TPST Tempest Therapeutics, Inc. Stock Quote

TPST [NASD]

Index	-	P/E	-	EPS (ttm)	-24.99	Insider Own	1.10%	Shs Outstand	0.93M	Perf Week	-15.74%
Market Cap	88.86M	Forward P/E	-	EPS next Y	-4.61	Insider Trans	0.00%	Shs Float	-	Perf Month	-18.35%
Income	-26.10M	PEG	-	EPS next Q	-1.11	Inst Own	27.40%	Short Float	-	Perf Quarter	-24.86%
Sales	-	P/S	-	EPS this Y	40.60%	Inst Trans	-	Short Ratio	0.73	Perf Half Y	-19.51%
Book/sh	51.99	P/B	0.23	EPS next Y	35.50%	ROA	-52.40%	Target Price	37.00	Perf Year	-55.51%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-72.00%	52W Range	10.39 - 41.55	Perf YTD	-62.99%
Dividend	-	P/FCF	-	EPS past 5Y	45.60%	ROI	-	52W High	-71.41%	Beta	0.40
Dividend %	-	Quick Ratio	7.20	Sales past 5Y	-	Gross Margin	-	52W Low	14.40%	ATR	0.88
Employees	12	Current Ratio	7.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	28.54	Volatility	6.20% 5.71%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	9.50%	Profit Margin	-	Rel Volume	0.21	Prev Close	12.15
Shortable	Yes	LT Debt/Eq	0.31	Earnings	-	Payout	-	Avg Volume	111.70K	Price	11.88
Recom	2.00	SMA20	-17.92%	SMA50	-17.68%	SMA200	-41.60%	Volume	23,029	Change	-2.22%

Oct-01-21 08:00AM	Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting GlobeNewswire
Sep-20-21 08:00AM	Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche GlobeNewswire
Sep-13-21 08:00AM	Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target GlobeNewswire
Sep-09-21 04:01PM	Tempest to Present at Upcoming Investor Conferences GlobeNewswire
Aug-12-21 04:01PM	Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights GlobeNewswire
Aug-09-21 08:00AM	Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors GlobeNewswire +8.09%
Jul-09-21 08:00AM	Tempest to Participate in William Blair 2021 Biotech Focus Conference GlobeNewswire +49.38%
Jul-01-21 04:00PM	Tempest Announces Appointment of Christine Pellizzari to its Board of Directors GlobeNewswire

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience